BioWorld

Dec. 14, 2005

Vertex, GSK In Potential $405M VX-409 Preclinical Collaboration

Partnering a promising preclinical pain product, Vertex Pharmaceuticals Inc. granted GlaxoSmithKline plc worldwide development and commercialization rights in a deal worth up to $405 million plus royalties. (BioWorld Today) Read More

Insmed's iPlex: Second Orphan Drug Approved In Short Stature

Missed Phase II Velafermin Endpoint Drops CuraGen

Halozyme's Stock Sale Raising $16.1M After Nod For Hylenex

Other News To Note

ASH Roundup

Today's news in brief

BioWorld

BioWorld briefs for Jan 12, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Jan. 12, 2026.

3D rendering of antibody drug conjugated with cytotoxic payload

ADCs’ breakout 2025 and their still-unfinished potential

BioWorld Science

Over the course of the year, and continuing into the latest scientific meetings, an extraordinary breadth of new antibody-drug conjugate (ADC) designs was...

LINC01116 has prognostic value in lung cancer, study shows

BioWorld Science

Long noncoding RNAs (lncRNAs) have emerged as potential markers of disease, since they associate with proteins that regulate gene expression, translation or...

ADCs’ breakout 2025 and their still-unfinished potential

BioWorld

Over the course of the year, and continuing into the latest scientific meetings, an extraordinary breadth of new antibody-drug conjugate (ADC) designs was...